1. Home
  2. AVXL vs BDN Comparison

AVXL vs BDN Comparison

Compare AVXL & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • BDN
  • Stock Information
  • Founded
  • AVXL 2004
  • BDN 1986
  • Country
  • AVXL United States
  • BDN United States
  • Employees
  • AVXL N/A
  • BDN N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • BDN Real Estate Investment Trusts
  • Sector
  • AVXL Health Care
  • BDN Real Estate
  • Exchange
  • AVXL Nasdaq
  • BDN Nasdaq
  • Market Cap
  • AVXL 794.0M
  • BDN 731.6M
  • IPO Year
  • AVXL N/A
  • BDN N/A
  • Fundamental
  • Price
  • AVXL $9.32
  • BDN $4.31
  • Analyst Decision
  • AVXL Strong Buy
  • BDN Hold
  • Analyst Count
  • AVXL 2
  • BDN 1
  • Target Price
  • AVXL $44.00
  • BDN $5.00
  • AVG Volume (30 Days)
  • AVXL 927.5K
  • BDN 2.3M
  • Earning Date
  • AVXL 08-05-2025
  • BDN 07-23-2025
  • Dividend Yield
  • AVXL N/A
  • BDN 13.87%
  • EPS Growth
  • AVXL N/A
  • BDN N/A
  • EPS
  • AVXL N/A
  • BDN N/A
  • Revenue
  • AVXL N/A
  • BDN $312,538,000.00
  • Revenue This Year
  • AVXL N/A
  • BDN $57.76
  • Revenue Next Year
  • AVXL N/A
  • BDN $5.16
  • P/E Ratio
  • AVXL N/A
  • BDN N/A
  • Revenue Growth
  • AVXL N/A
  • BDN N/A
  • 52 Week Low
  • AVXL $4.00
  • BDN $3.41
  • 52 Week High
  • AVXL $14.44
  • BDN $6.54
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 60.62
  • BDN 47.18
  • Support Level
  • AVXL $9.09
  • BDN $4.19
  • Resistance Level
  • AVXL $9.78
  • BDN $4.34
  • Average True Range (ATR)
  • AVXL 0.41
  • BDN 0.13
  • MACD
  • AVXL 0.09
  • BDN -0.03
  • Stochastic Oscillator
  • AVXL 71.58
  • BDN 28.00

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About BDN Brandywine Realty Trust

Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.

Share on Social Networks: